Book a meeting
DO-BO

How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing strategy.

They discuss why the US is no longer an isolated “free pricing” island, how UK and EU prices can now feed back into US revenues, and why small and mid‑size biotechs, in particular, can no longer afford to treat US and ex‑US strategies as separate worlds.

If you’re in pharma/biotech, pricing & market access or RWE, and you’re not yet stress‑testing your global evidence, price floors and launch plan against MFN and NICE reforms, this episode is your wake‑up call.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier?

By

Stefan Walzer

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost)

By

Stefan Walzer

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

Is the EU “Launch Obligation” Really as Scary as It Sounds, Dr. Alexander Natz?

By

Stefan Walzer

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]